Clinical trials: Cardiovascular Diseases Risk
Shock, Cardiogenic, High Risk Percutaneous Coronary Interventions
Synchronized Cardiac Assist for Cardiogenic Shock
The purpose of this study is to collect prospective safety and performance information for the i-COR® device using synchronized cardiac assist in the setting of combined heart-lung failure or in high risk percutaneous…
- Trial name
- NCT02697006
- Testing
- i-cor Synchronized Cardiac Assist Device
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- Xenios AG
Coronary Heart Disease
A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
This study will assess the safety, tolerability and efficacy of RO4607381 in patients with coronary heart disease (CHD) or CHD risk equivalents.
- Trial name
- NCT00655538
- Testing
- dalcetrapib
- Where
- 23 sites in Austria, France and 5 more
- Volunteers
- 476 people
- Sponsor
- Hoffmann-La Roche
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Atherosclerosis
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
- Trial name
- STABILITY (NCT00799903)
- Testing
- Darapladib
- Where
- 650 sites in United States, Argentina and 37 more
- Volunteers
- 15,828 people
- Sponsor
- GlaxoSmithKline
Carotid Atherosclerosis, Carotid Artery Disease
ACCULINK for Revascularization of Carotids in High Risk Patients "The ARCHeR Trial"
1. To evaluate the safety and efficacy of the over-the-wire (OTW) ACCULINK (tm) System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA) 2.
- Trial name
- NCT00180518
- Testing
- Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system
- Volunteers
- 581 people
- Sponsor
- Abbott Medical Devices
Chronic Phase Chronic Myeloid Leukemia
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
This non-interventional, prospective study will characterize the impact of three approved first and second generation BCR-ABL1 tyrosine kinase inhibitors on cardiovascular and metabolic risk factors in chronic phase CML (CP-CML)…
- Trial name
- NCT03045120
- Where
- 24 sites in United States
- Volunteers
- 118 people
- Sponsor
- Bristol-Myers Squibb
Erectile Dysfunction
Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk
Evaluate satisfaction in people treated with IPDE5 inhibitors over time
- Trial name
- TIERRA (NCT00874185)
- Volunteers
- 720 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Fibrillation, Atrial, Atrial Fibrillation
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for…
- Trial name
- NCT00240643
- Testing
- SB424323
- Where
- 116 sites in United States, Argentina and 23 more
- Volunteers
- 640 people
- Sponsor
- GlaxoSmithKline
Coronary Stenosis, Acute Coronary Syndrome
Multiomics and Imaging-based Assessment of Vulnerable Coronary Plaques in Acute Coronary Syndromes
The aim of Multiplaque clinical study is to assess the vulnerability degree of the atheromatous plaques, before and after a myocardial infarction (MI), based on multiomics analysis, associated with invasive and non-invasive data.
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atheromatous Plaques
- Trial name
- MultiPlaque (NCT03391908)
- Testing
- cardiac imaging tests
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Coronary Artery Disease (CAD)
Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG
This is a 26-week (with a 26-week extension) multicenter, randomized, double-blind, placebo-controlled Phase 2 study of XC001 versus placebo.
- Trial name
- EXACT-CABG (NCT07118449)
- Testing
- XC001
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- XyloCor Therapeutics, Inc.
Carotid Artery Diseases
A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach
The objective of this study is to evaluate acute device and technical success of the CGuard Prime™ Carotid Stent System (80cm) when used in conjunction with the Enroute NPS during Transcarotid Artery Revascularization procedures…
- Trial name
- NCT06653387
- Testing
- CGuard Prime 80cm stent system
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- InspireMD
Cardiovascular Risk Factors, Hyperlipidemia
European Study of Cardiovascular Risk
The main objective of this study is to describe the management of patients with cardiovascular risk factors in primary prevention among different European countries.
- Conditions
- Cardiovascular Risk Factors, Hyperlipidemia, Hypertension, Diabetes
- Trial name
- EURIKA (NCT00882336)
- Where
- 775 sites in Austria, Belgium and 10 more
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Obesity and Cardiovascular Risk
Obesity and Cardiovascular Diseases, Cross-sectional Study in Saudi Arabia
The purpose of this research study is to collect information on participants body weight, blood sugar levels, heart related diseases and lifestyle.
- Trial name
- OCCURS (NCT05642533)
- Testing
- No treatment given
- Volunteers
- 1,061 people
- Sponsor
- Novo Nordisk A/S
Symptomatic Severe Aortic Stenosis
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate
The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, and severe aortic…
- Trial name
- PII S3i (NCT03222128)
- Testing
- TAVR
- Where
- 51 sites in United States
- Volunteers
- 1,074 people
- Sponsor
- Edwards Lifesciences
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular…
- Trial name
- NCT00249873
- Testing
- clopidogrel (SR25990C)
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 7,554 people
- Sponsor
- Sanofi
Prostate Cancer
A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide
This observational study aims to better understand the risk of serious heart-related problems in older men with advanced prostate cancer who are treated with certain commonly used medicines.
- Trial name
- NCT07672119
- Testing
- No intervention
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Bayer
Coronary Heart Disease (CHD)
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a…
- Trial name
- VESALIUS-CV (NCT03872401)
- Testing
- Evolocumab
- Where
- 852 sites in United States, Argentina and 31 more
- Volunteers
- 12,301 people
- Sponsor
- Amgen
Venous Thromboembolism
Prophylactic Use of Sodium Enoxaparin for Venous Thromboembolism in High-Risk Abdominal Surgery
The purpose of this study is to compare the safety and security and efficacy of sodium enoxaparin Cristália Produtos Químicos Farmaceuticos Ltda - Endocris with Clexane (Sanofi-Aventis) to prevent Venous Thromboembolism in…
- Trial name
- NCT01308528
- Testing
- Sodium enoxaparin, Sodium Enoxaparin clexane
- Where
- 9 sites in Brazil
- Volunteers
- 243 people
- Sponsor
- Cristália Produtos Químicos Farmacêuticos Ltda.
Blood Circulation Disorder, Deep Vein Thrombosis
CEFID-II (CEra Flow Improves DVT-II)
For Deep Vein Thrombosis (DVT) risk groups, the effect and safety of blood circulation improvement before and after application are evaluated using an investigational device (model name CGM MB-1701).
- Trial name
- NCT05511064
- Testing
- Blood circulation device
- Where
- 3 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Ceragem Clinical Inc.